Topic is suspended
Status Suspended
Process TAG


Key events during the development of the guidance:

Date Update
04 March 2021 The Topic Selection Oversight Panel concluded that as a new formulation of an already existing agent, Pertuzumab–trastuzumab with chemotherapy is not a significant licence extension to progress through to Technology Appraisal assessment. The appraisal is therefore suspended from the NICE work programme. Access to this treatment is managed through NHS England and Improvement routine commissioning.
08 January 2021 Suspended. Topic is suspended
10 January 2020 In progress. Referred October 28 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance